Analysis of Characteristics and Risk Factors of Patients with Single Gastric Cancer and Synchronous Multiple Gastric Cancer among 14,603 Patients
Du Hyun Song,Nayoung Kim,Hyeong Ho Jo,Sangbin Kim,Yonghoon Choi,Hyeon Jeong Oh,Hye Seung Lee,Hyuk Yoon,Cheol Min Shin,Young Soo Park,Dong Ho Lee,So Hyun Kang,Young Suk Park,Sang-Hoon Ahn,Yun-Suhk Suh,Do Joong Park,Hyung Ho Kim,Ji-Won Kim,Jin Won Kim,Keun-Wook Lee,Won Chang,Ji Hoon Park,Yoon Jin Lee,Kyoung Ho Lee,Young Hoon Kim,Soyeon Ahn,Young-Joon Surh
DOI: https://doi.org/10.5009/gnl220491
2024-03-15
Abstract:Background/aims: Synchronous multiple gastric cancer (SMGC) accounts for approximately 6% to 14% of gastric cancer (GC) cases. This study aimed to identify risk factors for SMGC. Methods: A total of 14,603 patients diagnosed with GC were prospectively enrolled. Data including age, sex, body mass index, smoking, alcohol consumption, family history, p53 expression, microsatellite instability, cancer classification, lymph node metastasis, and treatment were collected. Risk factors were analyzed using logistic regression analysis between a single GC and SMGC. Results: The incidence of SMGC was 4.04%, and that of early GC (EGC) and advanced GC (AGC) was 5.43% and 3.11%, respectively. Patients with SMGC were older (65.33 years vs 61.75 years, p<0.001) and more likely to be male. Lymph node metastasis was found in 27% of patients with SMGC and 32% of patients with single GC. Multivariate analysis showed that SMGC was associated with sex (male odds ratio [OR], 1.669; 95% confidence interval [CI], 1.223 to 2.278; p=0.001), age (≥65 years OR, 1.532; 95% CI, 1.169 to 2.008; p=0.002), and EGC (OR, 1.929; 95% CI, 1.432 to 2.600; p<0.001). Survival rates were affected by Lauren classification, sex, tumor size, cancer type, distant metastasis, and venous invasion but were not related to the number of GCs. However, the survival rate of AGC with SMGC was very high. Conclusions: SMGC had unique characteristics such as male sex, older age, and EGC, and the survival rate of AGC, in which the intestinal type was much more frequent, was very good (Trial registration number: NCT04973631).